Bartlett JB - Search Results

1

The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Bartlett JB, Dredge K, Dalgleish AG. Bartlett JB, et al. Nat Rev Cancer. 2004 Apr;4(4):314-22. doi: 10.1038/nrc1323. Nat Rev Cancer. 2004. PMID: 15057291 Review. No abstract available.

2

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Galustian C, et al. Among authors: bartlett jb. Expert Opin Biol Ther. 2004 Dec;4(12):1963-70. doi: 10.1517/14712598.4.12.1963. Expert Opin Biol Ther. 2004. PMID: 15571458 Review.

3

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG. Bartlett JB, et al. Br J Cancer. 2004 Mar 8;90(5):955-61. doi: 10.1038/sj.bjc.6601579. Br J Cancer. 2004. PMID: 14997189 Free PMC article. Clinical Trial.

4

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. Galustian C, et al. Among authors: bartlett jb. Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. doi: 10.1007/s00262-008-0620-4. Epub 2008 Nov 14. Cancer Immunol Immunother. 2009. PMID: 19009291 Free PMC article.

5

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).

Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Liu WM, et al. Among authors: bartlett jb. Br J Cancer. 2009 Sep 1;101(5):803-12. doi: 10.1038/sj.bjc.6605206. Epub 2009 Jul 28. Br J Cancer. 2009. PMID: 19638977 Free PMC article.

6

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB. Dredge K, et al. Among authors: bartlett jb. Microvasc Res. 2005 Jan;69(1-2):56-63. doi: 10.1016/j.mvr.2005.01.002. Microvasc Res. 2005. PMID: 15797261

7

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG. Schey SA, et al. Among authors: bartlett jb. J Clin Oncol. 2004 Aug 15;22(16):3269-76. doi: 10.1200/JCO.2004.10.052. Epub 2004 Jul 12. J Clin Oncol. 2004. PMID: 15249589 Clinical Trial.

8

The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival.

Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG, Kumar D. Evans C, et al. Among authors: bartlett jb. Br J Cancer. 2006 May 22;94(10):1412-9. doi: 10.1038/sj.bjc.6603104. Br J Cancer. 2006. PMID: 16641913 Free PMC article.

9

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Henry JY, et al. Among authors: bartlett jb. Prostate. 2012 Jun 1;72(8):856-67. doi: 10.1002/pros.21488. Epub 2011 Oct 3. Prostate. 2012. PMID: 21968939

10

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.

Bartlett JB, Tozer A, Stirling D, Zeldis JB. Bartlett JB, et al. Br J Cancer. 2005 Sep 19;93(6):613-9. doi: 10.1038/sj.bjc.6602774. Br J Cancer. 2005. PMID: 16222306 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page